1. Search Result
Search Result
Results for "

Oxytocin receptor

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

1

Biochemical Assay Reagents

21

Peptides

1

Recombinant Proteins

2

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15015

    Oxytocin receptor antagonist 1

    Oxytocin Receptor Endocrinology
    OT-R antagonist 1 is a new potent and selective nonpeptide low molecular weight OT-R antagonist.
    OT-R antagonist 1
  • HY-15015A

    Oxytocin receptor antagonist 2

    Oxytocin Receptor Endocrinology
    OT-R antagonist 2 is a nonpeptide low molecular weight OT-R antagonist.
    OT-R antagonist 2
  • HY-153963

    Oxytocin Receptor Endocrinology
    PF-06655075 is a novel andnon–brain-penetrant oxytocin receptor agonist with increased selectivity for the oxytocin receptor and significantly increased pharmacokinetic stability. PF-06655075 can be used as a tool compound to further explore the role of peripheral oxytocin in behavioral response .
    PF-06655075
  • HY-108677
    L-368,899 hydrochloride
    3 Publications Verification

    Oxytocin Receptor Endocrinology
    L-368,899 hydrochloride is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC50s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively. L-368,899 hydrochloride used as a tocolytic agent .
    L-368,899 hydrochloride
  • HY-P2034

    Oxytocin Receptor Endocrinology
    Cargutocin, an oxytocin analogue, targets the oxytocin receptor and acts as a uterine contraction agent .
    Cargutocin
  • HY-153963A

    Oxytocin Receptor Endocrinology
    PF-06655075 (TFA) is the TFA form of PF-06655075 (HY-153963). PF-06655075 is a novel andnon–brain-penetrant oxytocin receptor agonist with increased selectivity for the oxytocin receptor and significantly increased pharmacokinetic stability. PF-06655075 can be used as a tool compound to further explore the role of peripheral oxytocin in behavioral response .
    PF-06655075 TFA
  • HY-P4895

    Oxytocin Receptor Neurological Disease
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin
  • HY-153964

    Oxytocin Receptor Cardiovascular Disease
    PF-06478939 is a non-brain-penetrating peptide that is an agonist at oxytocin (OT) receptor and vasopressin receptor with EC50 values of 0.01 nM and 0.078 nM, respectively .
    PF-06478939
  • HY-153964A

    Oxytocin Receptor Cardiovascular Disease
    PF-06478939 TFA is a non-brain-penetrating peptide that is an agonist at oxytocin (OT) receptor and vasopressin receptor with EC50 values of 0.01 nM and 0.078 nM, respectively .
    PF-06478939 TFA
  • HY-108679

    Oxytocin Receptor Neurological Disease
    WAY-267464 hydrochloride is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 hydrochloride can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 hydrochloride can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464 hydrochloride
  • HY-15023
    Cligosiban
    Maximum Cited Publications
    6 Publications Verification

    PF-3274167

    Oxytocin Receptor Endocrinology
    Cligosiban (PF-3274167) is an orally active, highly selective, and centrally permeable oxytocin receptor antagonist with good pharmacokinetics in rats and can inhibit physiological ejaculation in rodents [1][2].
    Cligosiban
  • HY-15522

    Oxytocin Receptor Neurological Disease
    WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464
  • HY-P4994

    Vasopressin Receptor Cardiovascular Disease
    Val9-Oxytocin is a full antagonist of vasopressin (V1a) receptor. Val9-Oxytocin is an analog of Oxytocin (HY-17571A) in which changing Gly9 to Val9 .
    Val9-Oxytocin
  • HY-105018

    GSK 557296

    Oxytocin Receptor Endocrinology
    Epelsiban (GSK 557296) is a potent, selective and orally bioavailable oxytocin receptor antagonist, with a pKi of 9.9 for human oxytocin receptor.
    Epelsiban
  • HY-P5017

    Oxytocin Receptor Endocrinology
    (Val3,Pro8)-Oxytocin is the Gq-dependent pathway agonist. (Val3,Pro8)-Oxytocin is also a weaker agonist for the β-arrestin engagement and endocytosis toward the oxytocin receptor (OXTR) .
    (Val3,Pro8)-Oxytocin
  • HY-17573
    Carbetocin
    1 Publications Verification

    Oxytocin Receptor Neurological Disease Endocrinology
    Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .
    Carbetocin
  • HY-17573A
    Carbetocin acetate
    1 Publications Verification

    Oxytocin Receptor Neurological Disease Endocrinology
    Carbetocin acetate, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin acetate has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin acetate has the potential for postpartum hemorrhage research. Carbetocin acetate can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .
    Carbetocin acetate
  • HY-P3467

    Oxytocin Receptor Potassium Channel Neurological Disease
    (Thr4,Gly7)-Oxytocin, an Oxytocin analogue, is a specific OT receptor agonist. (Thr4,Gly7)-Oxytocin also excites subicular neurons via activation of TRPV1 channels, and depression of K + channels. .
    (Thr4,Gly7)-Oxytocin
  • HY-17573R

    Oxytocin Receptor Neurological Disease Endocrinology
    Carbetocin (Standard) is the analytical standard of Carbetocin. This product is intended for research and analytical applications. Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .
    Carbetocin (Standard)
  • HY-17572
    Atosiban
    4 Publications Verification

    RW22164; RWJ22164

    Oxytocin Receptor Vasopressin Receptor Endocrinology Cancer
    Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research .
    Atosiban
  • HY-15010

    Oxytocin Receptor Vasopressin Receptor Endocrinology
    L-371,257 is an orally bioavailable, non-blood-brain barrier penetrant, selective and competitive antagonist of oxytocin receptor (pA2=8.4) with high affinity at both the oxytocin receptor (Ki=19 nM) and vasopressin V1a receptor (Ki=3.7 nM) .
    L-371,257
  • HY-108678

    Oxytocin Receptor Vasopressin Receptor Neurological Disease
    TC OT 39 is a synthetic oxytocin analog, as well as a selective agonist of oxytocin receptor (OXTR, EC50=180 nM). TC OT 39 is also an Avprla vasopressin receptor antagonist with an Ki value of 330 nM. TC OT 39 exhibits sedative effects in mouse models .
    TC OT 39
  • HY-17572A
    Atosiban acetate
    4 Publications Verification

    RW22164 acetate; RWJ22164 acetate

    Oxytocin Receptor Vasopressin Receptor Endocrinology Cancer
    Atosiban acetate (RW22164 acetate;RWJ22164 acetate) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research .
    Atosiban acetate
  • HY-105018A

    GSK 557296 benzenesulfonate

    Others Others
    Epelsiban Besylate (GSK 557296 benzenesulfonate) is an orally active compound known for its highly selective oxytocin receptor antagonist.
    Epelsiban besylate
  • HY-128351

    Oxytocin Receptor Neurological Disease Endocrinology
    SHR1653 is a highly potent, selective and brain penetrated oxytocin receptor (OTR) antagonist, with an IC50 of 15 nM for hOTR .
    SHR1653
  • HY-15018A

    Oxytocin Receptor Endocrinology
    SSR126768A free base is an orally active antagonist for oxytocin receptor, with Ki of 0.44 nM. SSR126768A free base is a tocolytic agent, that antagonizes the Oxytocin (HY-17571)-induced intracellular Ca 2+ increase and prostaglandin release in human uterine smooth muscle cells, inhibits thus the Oxytocin (HY-17571)-induced uterine contraction and delays parturition in pregnant rats in labor .
    SSR126768A free base
  • HY-17572R

    Oxytocin Receptor Vasopressin Receptor Endocrinology Cancer
    Atosiban (Standard) is the analytical standard of Atosiban. This product is intended for research and analytical applications. Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research .
    Atosiban (Standard)
  • HY-17572AR

    Oxytocin Receptor Vasopressin Receptor Endocrinology Cancer
    Atosiban (acetate) (Standard) is the analytical standard of Atosiban (acetate). This product is intended for research and analytical applications. Atosiban acetate (RW22164 acetate;RWJ22164 acetate) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research .
    Atosiban acetate (Standard)
  • HY-P4397

    Oxytocin Receptor Endocrinology
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin, an oxytocin receptor antagonist, abolishes oxytocin-enhanced inhibitory postsynaptic currents in CA1 pyramidal neurons .
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin
  • HY-W048739

    Amino Acid Derivatives Others
    Fmoc-α-Me-Leu-OH is a leucine derivative with an Fmoc protecting group, which can be used to synthesize peptides with oxytocin receptor agonist activity .
    Fmoc-α-Me-Leu-OH
  • HY-P2626

    Opioid Receptor Neurological Disease
    [D-Ala2]-Met-Enkephalin, an opioid peptide, is a potent opioid agonist. [D-Ala2]-Met-Enkephalin inhibits ACh-induced and suckling-induced oxytocin (OT) release .
    [D-Ala2]-Met-Enkephalin
  • HY-15008

    Oxytocin Receptor Endocrinology
    L-368,899 is an orally active and selective OT (oxytocin ) receptor antagonist, with IC50s of 8.9 and 26 nM for uterus of rat and human, respectively. L-368,899 can cross the blood-brain barrier (BBB). L-368,899 inhibits oxytocin-stimulated uterine contractions in rats and can be used in study of preterm labor .
    L-368,899
  • HY-59302

    Biochemical Assay Reagents Others
    Indole-5-carboxylic acid, 98% is an oxytocin that interacts with serotonin receptors and gamma-aminobutyric acid (GABA) receptors. It has also been reported to interact with various enzymes such as cyclooxygenase-2 (COX-2) and 5-hydroxytryptamine (5-HT) receptors.
    Indole-5-carboxylic acid, 98%
  • HY-P1390

    Vasopressin Receptor Endocrinology
    d[Cha4]-AVP is a potent and selective vasopressin (AVP) V1b receptor agonist with a Ki of 1.2 nM for human V1b receptor. d[Cha4]-AVP shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors .
    d[Cha4]-AVP
  • HY-124733A

    Oxytocin Receptor Neurological Disease
    LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism .
    LIT-001
  • HY-P1390A

    Vasopressin Receptor Endocrinology
    d[Cha4]-AVP TFA is a potent and selective vasopressin (AVP) V1b receptor agonist with a Ki of 1.2 nM for human V1b receptor. d[Cha4]-AVP TFA shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors .
    d[Cha4]-AVP TFA
  • HY-P10325

    Vasopressin Receptor Oxytocin Receptor Cardiovascular Disease
    Kalata B7 is a cyclotide that can be isolated from Oldenlandia affinis DC (Rubiaceae) and possesses membrane-permeating capabilities. Kalata B7 is also a partial agonist of oxytocin and vasopressin V1a receptors .
    Kalata B7
  • HY-124733

    Oxytocin Receptor Neurological Disease
    LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 free base improves social interaction in a mouse model of autism .
    LIT-001 free base
  • HY-P3516

    FE-200440

    Oxytocin Receptor Endocrinology
    Barusiban (FE-200440) is an oxytocin receptor (OT-R) antagonist (Ki=0.8 nM), inhibits OT-induced contraction. Barusiban can be used in preterm labor (PTL), in vitro fertilisation (IVF) and infertility research .
    Barusiban
  • HY-118918

    Vasopressin Receptor Endocrinology
    YM218 free base is an orally active non-peptide vasopressin (AVP) receptor antagonist. YM218 free base has a high affinity for rat liver V1A receptors with a Ki value of 0.50 nM; it has a lower affinity for rat pituitary V1B, kidney V2, and uterine oxytocin receptors with Ki values of 1510 nM, 72.2 nM, and 150 nM, respectively. YM218 free base can be used in the study of diabetes and kidney disease .
    YM218 free base
  • HY-15007

    Oxytocin Receptor Endocrinology
    L 366509 is a spiroindenylpiperidine camphorsulfonamide oxytocin (OT) antagonist. Modifications led to a new series of o-tolylpiperazine (TP) camphorsulfonamides, exhibiting high affinity for OT receptors and selectivity over arginine vasopressin receptors. Notably, compound 7 (L-368,899) showed excellent OT receptor affinity, potency in inhibiting OT-stimulated uterine contractions, good aqueous solubility, and oral bioavailability in multiple species. Compound 7 has entered clinical testing as an oral and intravenous tocolytic agent. Molecular modeling suggests the TP camphorsulfonamide structure mimics the D-AA2-Ile3 dipeptide, crucial in potent OT antagonists .
    L 366509
  • HY-117637

    Others Neurological Disease
    ALS-I-41 is a novel, potent and selective oxytocin receptor antagonist with the potential to modulate biological activities related to social behavior and mental disorders. ALS-I-41 is being evaluated for behavioral pharmacology experiments in non-human primates and can be administered via intranasal or intramuscular injection. The central nervous system penetration and metabolic rate of ALS-I-41 were studied by mass spectrometry analysis in cerebrospinal fluid and plasma of macaque monkeys .
    ALS-I-41

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: